Skip to main content
Toggle navigation
Main navigation
Home
About
About Us
Our Partners
Our People
Projects
Adverse Events of Special Interest in NZ Primary Care
COVID-19-SENT-[Africa-8]
Epidemiological assessment of adverse events following measles, mumps, and rubella (MMR) vaccination
Genomics of COVID-19 Vaccine-Induced Adverse Events
Global COVID Vaccine Safety (GCoVS)
SAFE [NZ background rates for AESI 2008–2019]
Resources
Blogs
Data Dashboard
News
Newsletter
Publications
Useful Links
Videos and Webinars
Contact
Search
Search
Collaborating on vaccine safety and effectiveness studies using health data from around the world.
Home
News
GVDN Mobile Menu
Home
About
About Us
Our Partners
Our People
Projects
Adverse Events of Special Interest in NZ Primary Care
COVID-19-SENT-[Africa-8]
Epidemiological assessment of adverse events following measles, mumps, and rubella (MMR) vaccination
Genomics of COVID-19 Vaccine-Induced Adverse Events
Global COVID Vaccine Safety (GCoVS)
SAFE [NZ background rates for AESI 2008–2019]
Resources
Blogs
Data Dashboard
News
Newsletter
Publications
Useful Links
Videos and Webinars
Contact
News
12 August 2022
Responding to the need: GVDN includes smallpox vaccine in global vaccine safety surveillance
20 April 2022
GVDN™ partners in Finland and Denmark review post-mRNA COVID vaccination myocarditis and pericarditis in 23 million Nordic residents
13 April 2022
Pandemic propels global effort to study rare vaccine side effects
